The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNFα. The system and method are useful for the treatment of different cancer types, stages and severity.

The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNFα. The system and method are useful for the treatment of different cancer types, stages and severity.

The present invention relates to a method for applying a principle of Deterministic Lateral Displacement (DLD), and for separating cells depending on the particle sizes on the basis of the DLD principle after capturing targeted cells or untargeted cells on a carrier and thereby increasing particle sizes.

Described herein are fluid-manipulation-based devices and methods of use. Fluid manipulations according to devices and methods as described herein can be configured to perform assays on biological samples. Devices and methods as described herein can manipulate and analyze nanoliter volumes of fluid, microliter volumes of fluid, milliliter volumes of fluid, or greater. Embodiments of the present disclosure can enable random biological assays and rapid, simultaneous analysis of multiple biological samples.

An improved method for the preparation of tetrameric antibody complexes directly on the surface of target entities in a sample is described. In particular, this method involves linking, in the sample, a first target entity with a second target entity in a sample using antibodies with specificity for the first and second target entities.

An object of the present invention is to find a component which can prevent non-specific flocculation of sensitized or unsensitized insoluble carrier particles contained in an immunoassay reagent when the reagent is frozen, to thereby provide means for preventing degradation of the immunoassay reagent. The component which can prevent non-specific flocculation of insoluble carrier particles is the following ω-aminocarboxylic acid (1) [wherein n is an integer of 2 to 6]. The invention provides an immunoassay reagent containing insoluble carrier particles and ω-aminocarboxylic acid (1), and a method for preventing degradation of an immunoassay reagent by using ω-aminocarboxylic acid (1).

##STR00001##

A sensor system that employs sub-pixel sized beads for assays is disclosed. The sensor system includes a first plurality of sensor pixels that define a first active sensor area. The first active sensor area is configured to receive a first portion of a fluid sample. The first portion is mixed with a plurality of first functionalized beads for performing a first assay. The sensor system also includes at least a second plurality of sensor pixels that define a second active sensor area. The second active sensor area is configured to receive a second portion of the fluid sample. The second portion is mixed with a second plurality of functionalized beads for performing a second assay. The first assay and the second assay may be configured to detect different concentration ranges of an analyte in the fluid sample.

This invention provides a stool specimen test device comprising: a suction port of a sample comprising a stool suspension; a sampling verification section that detect a specimen without the collected stool sample based on the absorbance of the stool suspension measured at the first wavelength; and a sample measurement section that performs measurement based on the absorbance measured at the second wavelength. This invention can improve the test accuracy by detecting a specimen without the collected stool sample in the stool specimen test.

Methods and kits for accurately detecting one or more analytes in a sample by removing non-specific binding signals utilizing capture and control microparticles. The capture microparticles can specifically bind to the analyte while the control microparticles do not specifically bind to the analyte but to the background molecules. Both capture and control microparticles are added to the sample under suitable conditions to allow binding between analytes and the microparticles. Detection agent is then added to bind to analytes and other substances captured by the microparticles. The microparticles are then run through a cytometry-based detection method, where detection signals from the capture and the control microparticles are distinguished. The differences between the detection signals from the capture and the control microparticles are obtained, which are then used to determine the presence and/or amounts of the analytes based on a previously determined relationship between such differences and known amount of the analyte.

Disclosed herein is the expression of beta-domain (Asp201-Gly339) of the VP2 protein (NCBI Acc. No. KT281984) of infectious bursal disease virus (IBDV), in codon optimized Rosetta 2 (DE3) strain of E. coli followed by its purification by affinity and gel filtration chromatography and use for development of dipstick and lateral flow strip for diagnosis of antibodies produced in chicken upon IBDV infection/vaccination.